Navigation Links
Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
Date:10/22/2007

NEW ORLEANS and PITTSBURGH, Oct. 22 /PRNewswire-FirstCall/ -- Data presented at the 2007 Annual Scientific Meeting of NAASO, The Obesity Society, found that patient satisfaction with alli(R) (orlistat 60mg), the only FDA- approved, over-the-counter (OTC) weight loss product, was connected to the product's effectiveness in helping them lose weight, and not to potential gastrointestinal (GI) treatment effects. This is important because these data show that the weight loss achieved with alli strongly motivates subjects to continue treatment regardless if they are experiencing treatment effects.

In the study, very few subjects (<5%) stopped taking alli because of treatment effects and were able to maximize their weight loss. Interestingly, treatment effects were viewed by many alli users as a positive feedback tool that helps them become more aware of hidden fats in foods.

Many patients have reported significant weight loss and high satisfaction when following the alli weight loss plan. Treatment effects are characterized by predictable GI side effects when alli is taken with meals with too much fat. "Since having my first child, I have been carrying around extra weight and now I'm a mother of three," said Jaime Clear, a 28-year-old alli First Team member from Henderson, Nevada. "I committed to losing the weight with alli and have lost 20 pounds in 10 weeks. The treatment effects have been manageable and have kept me honest about my diet." The alli First Team is a group of 406 men and women that was formed after alli was approved by the FDA, and given the opportunity to use alli at no cost before it was available in stores.

This cumulative data analysis evaluated controlled and non-controlled studies on alli (orlistat 60mg) to examine the overall tolerability profile. The analysis of controlled studies shows that during the first week of treatment with alli, the overall incidence of most treatment effects was generally low (3% to 8%). In addition the overall rate was 33 percent lower than the orlistat 120mg group. In fact, researchers determined that when alli was used for three months without physician supervision in a non-controlled setting, the overall incidence of treatment effects was 20 percent lower compared to controlled studies. These data support the proposition that most patients can successfully modify their eating habits to comply with the alli plan.

"The alli data we're reviewing show that treatment effects are not a major issue for most patients taking alli because they are highly motivated by the weight loss achieved. In addition, many alli users have repeatedly told us that they view treatment effects as a positive tool to help make them aware of hidden fats in foods. Thus, alli capsules, in addition to the alli program, provides patients with a powerful tool that they can use to achieve their weight loss goals and embrace healthier lifestyle behaviors," commented Vidhu Bansal-Dev, PharmD, director, Medical Affairs, GlaxoSmithKline Consumer Healthcare.

Consumer Feedback

In addition to the cumulative data analysis released at NAASO, recently collected consumer data show overall satisfaction with the alli weight loss program was ranked at 85 percent among alli First Team members. Moreover, a new consumer survey conducted by Nielsen and funded by GlaxoSmithKline Consumer Healthcare showed nearly 70 percent of people reported losing weight after starting the alli program.

About Overweight and Obesity

Currently, approximately 65 percent of U.S. adults are overweight or obese, according to the National Institutes of Health. Research suggests that overweight individuals appear to be on the pathway to obesity. Overweight and obesity are associated with an increased risk of developing health problems such as hypertension, type 2 diabetes and heart disease. Factors that can contribute to overweight include an abundance of high-calorie foods, low levels of physical activity, behavior, environment, and genetics. Multiple studies have shown that a modest reduction in weight improves health outcomes significantly in overweight or obese patients.

About alli(R) Weight Loss Aid

alli (orlistat 60mg), the only FDA-approved weight-loss product available to overweight adults without a prescription, combines a clinically-proven product with a comprehensive individualized action plan. The alli program encourages modest, gradual weight loss, known by experts as the best way to lose weight. alli is to be taken three times a day with meals containing fat and has been available in pharmacies and mass retailers nationwide since June 15, 2007.

About GlaxoSmithKline Consumer Healthcare

GSK Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ and Commit(R) as well as many medicine cabinet staples, including Abreva(R), Aquafresh(R), Sensodyne(R), Tums(R) and Breathe Right(R).

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: http://www.gsk.com.


'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
Breaking Medicine News(10 mins):